July 11 (Reuters) - Capricor Therapeutics Inc CAPR.O:
CAPRICOR THERAPEUTICS PROVIDES REGULATORY UPDATE ON DERAMIOCEL BLA FOR DUCHENNE MUSCULAR DYSTROPHY
CAPRICOR THERAPEUTICS INC - FDA ISSUES COMPLETE RESPONSE LETTER TO CAPRICOR
CAPRICOR THERAPEUTICS INC - TO RESUBMIT BLA WITH PHASE 3 DATA IN Q3 2025
CAPRICOR THERAPEUTICS INC - FDA ADVISES CAPRICOR TO REQUEST MEETING FOR APPROVAL
CAPRICOR THERAPEUTICS: FDA SAID DERAMIOCEL BLA DOES NOT MEET STATUTORY REQUIREMENT FOR SUBSTANTIAL EVIDENCE OF EFFECTIVENESS
Source text: ID:nGNX4r3vQz
Further company coverage: CAPR.O
((Reuters.Briefs@thomsonreuters.com;))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。